Loading...
Sanara MedTech delivered 26% year-over-year revenue growth in Q1 2025, driven primarily by strong sales of soft tissue repair products. However, the company reported a wider net loss due to increased investments in its Tissue Health Plus segment and corporate infrastructure expansion.
Sanara aims to drive continued revenue growth in the Sanara Surgical segment while launching pilot programs and seeking partners for its THP initiative.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance